Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 19, 2021 - Issue 12
Submit an article Journal homepage
153
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality

Francisco Aguilara Department of Medicine, Einstein Medical Center, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-2334-6915
ORCID Icon,
Kevin B. Loa Department of Medicine, Einstein Medical Center, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0001-7088-6677
ORCID Icon,
Eduardo E. Quinteroa Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA
,
Ricardo J. Torresa Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA
,
Wikien A. Hunga Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA
,
Jeri C. Albanoa Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA
,
Isabella Alvizb Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA
,
Carlos Rodriguezb Division of Cardiology, Montefiore Medical Center, Bronx, NY, USAORCID Iconhttps://orcid.org/0000-0003-0860-9008
ORCID Icon,
Mario J. Garciab Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA
,
Jorge Romerob Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA
&
Leandro Slipczukb Division of Cardiology, Montefiore Medical Center, Bronx, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3091-3735
ORCID Icon show all
Pages 1119-1126 | Received 03 Aug 2021, Accepted 30 Nov 2021, Published online: 22 Dec 2021

References

  • January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):2071–2104.
  • Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
  • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
  • Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–339.
  • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
  • tHylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–2147.
  • Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604.
  • Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018;9:1220.
  • Bell AD, Gross P, Heffernan M, et al. Appropriate use of antithrombotic medication in Canadian patients with nonvalvular atrial fibrillation. Am J Cardiol. 2016;117(7):1107–1111.
  • Camm AJ, Cools F, Virdone S, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–1436.
  • Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost. 2017 Jan 26;117(2):382–389.
  • Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019;12(8). DOI:https://doi.org/10.1161/CIRCOUTCOMES.118.005404
  • Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–314.
  • Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on. Eur Heart J. 2014;35(45):3155–3179.
  • Yao X, Shah ND, Sangaralingham LR, et al. Non–vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790.
  • Pirmohamed M. Warfarin: the end or the end of one size fits all therapy? J Pers Med. 2018;8(3). DOI:https://doi.org/10.3390/jpm8030022
  • Rozenblum R, Rodriguez-Monguio R, Volk LA, et al. Using a machine learning system to identify and prevent medication prescribing errors: a clinical and cost analysis evaluation. Jt Comm J Qual Patient Saf. 2020;46(1):3–10.
  • Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;31(4):749–753.
  • Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
  • Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379(14):1332–1342.
  • Van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019;139:775–786.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.